Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 8/20 | 0.72 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.72 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.57 |
| ▸ | LTA4H | P09960 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.56 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1745247 | 1.00 | FFAR1 (0.72) | FFAR1FFAR4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1745237 | 0.96 | FFAR1 (0.70) | FFAR1FFAR4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14305720 | 0.96 | FFAR1 (0.67) | FFAR1FFAR4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1744585 | 0.93 | FFAR1 (0.74) | FFAR1FFAR4 | |
| SCHEMBL1744673 | 0.93 | FFAR1 (0.74) | FFAR1FFAR4AKR1B1 | |
| SCHEMBL1746671 | 0.93 | FFAR1 (0.74) | FFAR1FFAR4 | |
| SCHEMBL1745369 | 0.92 | FFAR1 (0.76) | FFAR1FFAR4AKR1B1 | |
| SCHEMBL1860911 | 0.91 | FFAR1 (0.64) | FFAR1FFAR4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1747202 | 0.90 | SMN1; SMN2 (0.67) | FFAR1FFAR4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1745339 | 0.90 | FFAR1 (0.62) | FFAR1FFAR4AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1438310-B1 | BETA-CARBOLIN DERIVATIVES AS PTP-INHIBITORS | TRANSTECH PHARMA INC (US) | 2006-12-20 | — | — | EP | claimed |
| US-6933303-B2 | Heteroaryl-fused nitrogen heterocycles as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2005-08-23 | — | — | US | claimed |
| EP-1438310-A1 | BETA-CARBOLIN DERIVATIVES AS PTP-INHIBITORS | TransTech Pharma Inc. (US) | 2004-07-21 | — | — | EP | claimed |
| US-20040014778-A1 | Heteroaryl - fused nitrogen heterocycles as therapeutic agents | VTVX HOLDINGS I LLC | 2004-01-22 | — | — | US | claimed |
| WO-2003033496-A1 | BETA-CARBOLIN DERIVATIVES AS PTP-INHIBITORS | TRANSTECH PHARMA, INC. (US) | 2003-04-24 | — | — | WO | claimed |
| US-9469665-B2 | Compound having lysophosphatidylserine receptor function modulation activity | THE UNIVERSITY OF TOKYO (JP) | 2016-10-18 | — | — | US | disclosed |
| US-20150361119-A1 | COMPOUND HAVING LYSOPHOSPHATIDYLSERINE RECEPTOR FUNCTION MODULATION ACTIVITY | TOHOKU UNIVERSITY (JP) | 2015-12-17 | — | — | US | disclosed |
| EP-2952517-A1 | COMPOUND EXHIBITING REGULATORY ACTIVITY ON LYSOPHOSPHATIDYLSERINE RECEPTOR FUNCTION | The University of Tokyo (JP) | 2015-12-09 | — | — | EP | disclosed |
| EP-1559422-B1 | RECEPTOR FUNCTION CONTROLLING AGENT | TAKEDA PHARMACEUTICAL (JP) | 2014-04-30 | — | — | EP | disclosed |
| EP-2139843-B1 | SUBSTITUTED BIPHENYL PHENOXY-, THIOPHENYL- AND AMINOPHENYLPROPANOIC ACID GPR40 MODULATORS | AMGEN INC (US) | 2013-12-25 | — | — | EP | disclosed |
| EP-2385032-A1 | GPR40 Receptor function regulator | Takeda Pharmaceutical Company Limited (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-8008525-B2 | For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-30 | — | — | US | disclosed |
| WO-2003095441-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2003-11-20 | — | — | WO | disclosed |
| WO-2003033496-A1 | BETA-CARBOLIN DERIVATIVES AS PTP-INHIBITORS | TRANSTECH PHARMA, INC. (US) | 2003-04-24 | — | — | WO | disclosed |
| WO-2002100813-A2 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | ELI LILLY AND COMPANY (US) | 2002-12-19 | — | — | WO | disclosed |
| US-6414179-B1 | USEFUL AGENTS IN THE TREATMENT OF INFLAMMATORY DISEASES SUCH AS ASTHMA, ARTHRITIS, INFLAMMATORY BOWEL DISEASE AND NEURODEGENERATIVE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2002-07-02 | — | — | US | disclosed |
| US-20020065246-A1 | Alpha-and beta- substituted trifluoromethyl ketones as phospholipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-05-30 | — | — | US | disclosed |
| WO-1996035713-A1 | DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE | PFIZER, INC. (US) | 1996-11-14 | — | — | WO | disclosed |
| US-4761420-A | CARDIOVASCULAR DISORDERS | LABORATOIRES SYNTEX S.A. (FR) | 1988-08-02 | — | — | US | disclosed |
| EP-0249245-A2 | Antihypertensive dihydropyridine derivatives | LABORATOIRES SYNTEX S.A. (FR) | 1987-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014778-A1 | Heteroaryl - fused nitrogen heterocycles as therapeutic agents | PTPRG, PTPRM, PTPRC | FFAR1 1889/4885FFAR4 2326/4885NPC1 2380/4885 |
| US-20150361119-A1 | COMPOUND HAVING LYSOPHOSPHATIDYLSERINE RECEPTOR FUNCTION MODULATION ACTIVITY | LPAR1, LPAR3, LPAR2 | FFAR1 57/4885FFAR4 75/4885NPC1 1133/4885 |
| US-20020065246-A1 | Alpha-and beta- substituted trifluoromethyl ketones as phospholipase inhibitors | PLA2G4B, PLA2G1B, PLA2R1 | FFAR1 46/4885FFAR4 164/4885NPC1 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.